Your browser doesn't support javascript.
loading
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.
Cheung, Alfred K; Chang, Tara I; Cushman, William C; Furth, Susan L; Hou, Fan Fan; Ix, Joachim H; Knoll, Gregory A; Muntner, Paul; Pecoits-Filho, Roberto; Sarnak, Mark J; Tobe, Sheldon W; Tomson, Charles R V; Lytvyn, Lyubov; Craig, Jonathan C; Tunnicliffe, David J; Howell, Martin; Tonelli, Marcello; Cheung, Michael; Earley, Amy; Mann, Johannes F E.
Afiliación
  • Cheung AK; Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah, USA. Electronic address: Alfred.Cheung@hsc.utah.edu.
  • Chang TI; Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA.
  • Cushman WC; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Furth SL; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Hou FF; Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Ix JH; Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA; Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California, USA.
  • Knoll GA; Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Muntner P; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Pecoits-Filho R; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA; School of Medicine, Pontifical Catholic University of Paraná, Curitiba, Paraná, Brazil.
  • Sarnak MJ; Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Tobe SW; Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
  • Tomson CRV; Consultant Nephrologist, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Lytvyn L; MAGIC Evidence Ecosystem Foundation, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Craig JC; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia; Cochrane Kidney and Transplant, Sydney, New South Wales, Australia.
  • Tunnicliffe DJ; Cochrane Kidney and Transplant, Sydney, New South Wales, Australia; Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Howell M; Cochrane Kidney and Transplant, Sydney, New South Wales, Australia; Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Tonelli M; University of Calgary, Calgary, Alberta, Canada.
  • Cheung M; KDIGO, Brussels, Belgium.
  • Earley A; KDIGO, Brussels, Belgium.
  • Mann JFE; KfH Kidney Center, Munich, Germany; Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany. Electronic address: Johannes.mann@kms.mhn.de.
Kidney Int ; 99(3): 559-569, 2021 03.
Article en En | MEDLINE | ID: mdl-33637203
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Kidney Int Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Kidney Int Año: 2021 Tipo del documento: Article